Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung.
Kristin BairdJohn GlodSeth M SteinbergDenise K ReinkeJoseph G PresseyLeo MascarenhasNoah C FedermanNeyssa MarinaSant ChawlaJoanne P LagmayJohn GoldbergMohammed M MilhemDavid M LoebJames E ButrynskiBrian TurpinArthur StaddonSheri L SpuntRobin L JonesEve T RodlerScott M SchuetzeScott H OkunoLee HelmanPublished in: Sarcoma (2020)
Although saracatinib was well tolerated in this patient population, there was no apparent impact of the drug in this double-blinded, placebo-controlled trial on OS, and Src inhibition alone may not be sufficient to suppress metastatic progression in osteosarcoma. There is a suggestion of potential clinical benefit as evidenced by longer PFS in patients randomized to saracatinib based on limited numbers of patients treated.
Keyphrases
- double blind
- placebo controlled
- clinical trial
- end stage renal disease
- open label
- phase ii
- phase iii
- study protocol
- small cell lung cancer
- squamous cell carcinoma
- prognostic factors
- case report
- peritoneal dialysis
- tyrosine kinase
- phase ii study
- randomized controlled trial
- magnetic resonance imaging
- magnetic resonance
- radiation therapy
- risk assessment
- computed tomography
- human health
- diffusion weighted imaging
- patient reported